Literature DB >> 30310953

Value proposition of PSMA-targeted α-particle radioligand therapy in metastatic prostate cancer.

Hossein Jadvar1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30310953     DOI： 10.1007/s00259-018-4191-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  19 in total

1.  225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.

Authors:  Clemens Kratochwil; Frank Bruchertseifer; Frederik L Giesel; Mirjam Weis; Frederik A Verburg; Felix Mottaghy; Klaus Kopka; Christos Apostolidis; Uwe Haberkorn; Alfred Morgenstern
Journal:  J Nucl Med       Date:  2016-07-07       Impact factor: 10.057

2.  Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.

Authors:  Clemens Kratochwil; Frank Bruchertseifer; Hendrik Rathke; Marcus Bronzel; Christos Apostolidis; Wilko Weichert; Uwe Haberkorn; Frederik L Giesel; Alfred Morgenstern
Journal:  J Nucl Med       Date:  2017-04-13       Impact factor: 10.057

3.  Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.

Authors:  Amey Bandekar; Charles Zhu; Rohit Jindal; Frank Bruchertseifer; Alfred Morgenstern; Stavroula Sofou
Journal:  J Nucl Med       Date:  2013-12-12       Impact factor: 10.057

Review 4.  α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 2.

Authors:  Sophie Poty; Lynn C Francesconi; Michael R McDevitt; Michael J Morris; Jason S Lewis
Journal:  J Nucl Med       Date:  2018-03-01       Impact factor: 10.057

5.  Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control.

Authors:  Clemens Kratochwil; Frank Bruchertseifer; Hendrik Rathke; Markus Hohenfellner; Frederik L Giesel; Uwe Haberkorn; Alfred Morgenstern
Journal:  J Nucl Med       Date:  2018-01-11       Impact factor: 10.057

6.  German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

Authors:  Kambiz Rahbar; Hojjat Ahmadzadehfar; Clemens Kratochwil; Uwe Haberkorn; Michael Schäfers; Markus Essler; Richard P Baum; Harshad R Kulkarni; Matthias Schmidt; Alexander Drzezga; Peter Bartenstein; Andreas Pfestroff; Markus Luster; Ulf Lützen; Marlies Marx; Vikas Prasad; Winfried Brenner; Alexander Heinzel; Felix M Mottaghy; Juri Ruf; Philipp Tobias Meyer; Martin Heuschkel; Maria Eveslage; Martin Bögemann; Wolfgang Peter Fendler; Bernd Joachim Krause
Journal:  J Nucl Med       Date:  2016-10-20       Impact factor: 10.057

Review 7.  Radiotheranostics in Cancer Diagnosis and Management.

Authors:  Hossein Jadvar; Xiaoyuan Chen; Weibo Cai; Umar Mahmood
Journal:  Radiology       Date:  2018-02       Impact factor: 11.105

Review 8.  Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.

Authors:  Harshad R Kulkarni; Aviral Singh; Thomas Langbein; Christiane Schuchardt; Dirk Mueller; Jingjing Zhang; Coline Lehmann; Richard P Baum
Journal:  Br J Radiol       Date:  2018-06-01       Impact factor: 3.039

Review 9.  PSMA Theranostics: Current Status and Future Directions.

Authors:  Kambiz Rahbar; Ali Afshar-Oromieh; Hossein Jadvar; Hojjat Ahmadzadehfar
Journal:  Mol Imaging       Date:  2018 Jan-Dec       Impact factor: 4.488

10.  Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617.

Authors:  Clemens Kratochwil; Karl Schmidt; Ali Afshar-Oromieh; Frank Bruchertseifer; Hendrik Rathke; Alfred Morgenstern; Uwe Haberkorn; Frederik L Giesel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-09-11       Impact factor: 9.236
View more
  1 in total

Review 1.  Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen.

Authors:  Masayuki Inubushi; Hiroyuki Miura; Ichiei Kuji; Kimiteru Ito; Ryogo Minamimoto
Journal:  Ann Nucl Med       Date:  2020-11-11       Impact factor: 2.668
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.